GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » Cyclically Adjusted Price-to-FCF

BioLine Rx (XTAE:BLRX) Cyclically Adjusted Price-to-FCF : (As of Jun. 11, 2024)


View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioLine Rx Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for BioLine Rx's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Cyclically Adjusted Price-to-FCF Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioLine Rx Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioLine Rx's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, BioLine Rx's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Cyclically Adjusted Price-to-FCF falls into.



BioLine Rx Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

BioLine Rx's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, BioLine Rx's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.048/131.7762*131.7762
=-0.048

Current CPI (Mar. 2024) = 131.7762.

BioLine Rx Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.480 100.560 -0.629
201409 -0.361 100.428 -0.474
201412 -0.517 99.070 -0.688
201503 -0.317 99.621 -0.419
201506 -0.355 100.684 -0.465
201509 -0.322 100.392 -0.423
201512 -0.232 99.792 -0.306
201603 -0.294 100.470 -0.386
201606 -0.218 101.688 -0.283
201609 -0.197 101.861 -0.255
201612 -0.259 101.863 -0.335
201703 -0.479 102.862 -0.614
201706 -0.168 103.349 -0.214
201709 -0.228 104.136 -0.289
201712 -0.239 104.011 -0.303
201803 -0.241 105.290 -0.302
201806 -0.218 106.317 -0.270
201809 -0.209 106.507 -0.259
201812 -0.500 105.998 -0.622
201903 -0.130 107.251 -0.160
201906 -0.165 108.070 -0.201
201909 -0.154 108.329 -0.187
201912 -0.128 108.420 -0.156
202003 -0.142 108.902 -0.172
202006 -0.094 108.767 -0.114
202009 -0.069 109.815 -0.083
202012 -0.064 109.897 -0.077
202103 -0.042 111.754 -0.050
202106 -0.038 114.631 -0.044
202109 -0.026 115.734 -0.030
202112 -0.029 117.630 -0.032
202203 -0.029 121.301 -0.032
202206 -0.033 125.017 -0.035
202209 -0.044 125.227 -0.046
202212 -0.024 125.222 -0.025
202303 -0.033 127.348 -0.034
202306 -0.040 128.729 -0.041
202309 -0.040 129.860 -0.041
202312 0.017 129.419 0.017
202403 -0.048 131.776 -0.048

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioLine Rx  (XTAE:BLRX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


BioLine Rx Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx (XTAE:BLRX) Business Description

Industry
Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx (XTAE:BLRX) Headlines

From GuruFocus

BioLineRx to Report First Quarter 2023 Results on May 24, 2023

By PRNewswire PRNewswire 05-17-2023